Virios Therapeutics is a development-stage biotechnology company, which engages in the improvement of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. Co.'s primary candidate, IMC-1, is a proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. We show 14 historical shares outstanding datapoints in our VIRI shares outstanding history coverage, used to compute VIRI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VIRI market cap history over the course of time is important for investors
interested in comparing VIRI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VIRI versus a peer is one thing; comparing
VIRI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VIRI can fluctuate over the course of history.
With this page we aim to empower investors researching VIRI by allowing them to research the VIRI market cap history. |
Free VIRI Email Alerts:
Video: The Importance of Market Cap
